Cargando…

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial

PURPOSE: The aim of this study was to evaluate whether indomethacin eye drops and intravitreal ranibizumab (IVR) injections would provide additional benefit over ranibizumab alone in the treatment of choroidal neovascularization (CNV). PARTICIPANTS AND METHODS: This was a randomized, prospective pil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Andrea, Scaroni, Nicolò, Gambicorti, Elena, Turano, Raffaele, Morescalchi, Francesco, Costagliola, Ciro, Semeraro, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877501/ https://www.ncbi.nlm.nih.gov/pubmed/29628756 http://dx.doi.org/10.2147/OPTH.S159672

Ejemplares similares

Current Trends about Inner Limiting Membrane Peeling in Surgery for Epiretinal Membranes
por: Semeraro, Francesco, et al.
Publicado: (2015)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Central Serous Chorioretinopathy: Pathogenesis and Management
por: Semeraro, Francesco, et al.
Publicado: (2019)

Proliferative Vitreoretinopathy after Eye Injuries: An Overexpression of Growth Factors and Cytokines Leading to a Retinal Keloid
por: Morescalchi, Francesco, et al.
Publicado: (2013)

Heavy Silicone Oil and Intraocular Inflammation
por: Morescalchi, Francesco, et al.
Publicado: (2014)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration
por: Parmeggiani, Francesco, et al.
Publicado: (2019)

A Novel Device to Exploit the Smartphone Camera for Fundus Photography
por: Russo, Andrea, et al.
Publicado: (2015)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Aflibercept in wet AMD: specific role and optimal use
por: Semeraro, F, et al.
Publicado: (2013)

Tamponade or Filling Effect: Changes of Forces in Myopic Eyes
por: Semeraro, Francesco, et al.
Publicado: (2014)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)

Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration
por: Parmeggiani, Francesco, et al.
Publicado: (2015)

Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study
por: Bandello, Francesco, et al.
Publicado: (2020)

Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
por: Kaiser, Peter K.
Publicado: (2007)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Rotsos, Tryfon, et al.
Publicado: (2010)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
por: Chang, Yi-Sheng, et al.
Publicado: (2018)

Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration
por: Maunz, Andreas, et al.
Publicado: (2023)

Mechanism of Inflammation in Age-Related Macular Degeneration
por: Parmeggiani, Francesco, et al.
Publicado: (2012)

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
por: Scalzo, G C, et al.
Publicado: (2010)

Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration
por: Nita, Małgorzata, et al.
Publicado: (2014)

Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration
por: Gohil, Rishma, et al.
Publicado: (2015)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova, Nadezhda P, et al.
Publicado: (2016)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Combined photodynamic therapy and intravitreal ranibizumab as treatment for extrafoveal choroidal neovascularization associated with age-related macular degeneration
por: Chhablani, Jay Kumar
Publicado: (2010)

Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy
por: Han, So Young, et al.
Publicado: (2015)

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
por: Sabour-Pickett, Sarah, et al.
Publicado: (2013)

Clinical Risk Factors for Poor Anatomic Response to Ranibizumab in Neovascular Age-Related Macular Degeneration§
por: Guber, Josef, et al.
Publicado: (2014)

Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration
por: Lee, Kang Hoon, et al.
Publicado: (2015)

Missed Hospital Appointments of Patients Receiving Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
por: Karampelas, Michael, et al.
Publicado: (2015)

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
por: Wang, Luping, et al.
Publicado: (2018)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont, Pear, et al.
Publicado: (2018)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
por: Rodríguez, Francisco Jose, et al.
Publicado: (2019)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration
por: Diack, Cheikh, et al.
Publicado: (2021)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_itrqcrrj85ssjg5jf9ok4j21el